Search Results

It has been reported that overexpression of HER-2/neu occurs in one third of breast and ovarian cancers and that overexpression is associated with poor prognosis. A polyclonal antibedy against HER-2/ neu oncoprotein was used to assess immunohistachemically the level of HER-2/neu expression in normal and malignant endometrial carcinoma. In 8 normal endometrial samples light to moderate(0- +2) staining for HER-2/neu was seen in the giands, and there was no variation in intensity of staining during the menstrual cycle, Among 15 endometrial adenocarcinomas. three(20%) were found to have heavier staiaing (+3) for HER-2/neu than was seen in normal endometrium. High expression of HER-2/neu was found in 50%(1/2) of patients with metastatic disease(stages III or more) compared with 15%(2/13) of patients with disease confined to the uterus(stage I). Survival of the 3 patients with high HER-2/neu expression was significantly worse than that of the 1.2 patients with normal HER-2/neu expression. (Median survival: 49. I vs 28. 7 months (p=0.0348)) Further studies are needed to determine the significance of HER-2/ neu overexpression in endometrial cancer.
Adenocarcinoma ; Breast ; Endometrial Neoplasms* ; Endometrium ; Female ; Humans ; Menstrual Cycle ; Ovarian Neoplasms ; Prognosis

1.Clinical Trial Design and Ethics.

2.Recognition and treatment of secondary causes of obesity.

3.An Expression of HER-2/neu Oncoprotein in Endometrial Cancer.

4.Gene 4 typing of group a rotaviruses isolated from Korea.

5.Capsule Endoscopy vs. Push Enteroscopy and Enteroclysis in Suspected Small-bowel Crohn's Disease.

6.Epidemiology of Narcotics and Psychedelics.

7.Hyperemesis Gravidarum and Thyroid Function.

8.Diagnosis and Treatment for the Tinnitus.

9.Primary treatment of tendon injury.

10.VP7 typing of group A rotaviruses(Rv) using reverse transcription-polymerase chain reaction(RT-PCR).

Display Mode

Output Records

File Type